471 related articles for article (PubMed ID: 30685572)
1. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
[TBL] [Abstract][Full Text] [Related]
2. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
3. Low Responsiveness of Basophils via FcεRI Reflects Disease Activity in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2019; 7(8):2835-2844.e7. PubMed ID: 31136822
[TBL] [Abstract][Full Text] [Related]
4. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.
Schoepke N; Asero R; Ellrich A; Ferrer M; Gimenez-Arnau A; E H Grattan C; Jakob T; Konstantinou GN; Raap U; Skov PS; Staubach P; Kromminga A; Zhang K; Bindslev-Jensen C; Daschner A; Kinaciyan T; Knol EF; Makris M; Marrouche N; Schmid-Grendelmeier P; Sussman G; Toubi E; Church MK; Maurer M
Allergy; 2019 Dec; 74(12):2427-2436. PubMed ID: 31228881
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
7. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.
Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
Allergy; 2017 Dec; 72(12):1904-1911. PubMed ID: 28585360
[TBL] [Abstract][Full Text] [Related]
8. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
[TBL] [Abstract][Full Text] [Related]
9. Basophil CD63 expression assay on highly sensitized atopic donor leucocytes-a useful method in chronic autoimmune urticaria.
Gyimesi E; Sipka S; Dankó K; Kiss E; Hídvégi B; Gál M; Hunyadi J; Irinyi B; Szegedi A
Br J Dermatol; 2004 Aug; 151(2):388-96. PubMed ID: 15327546
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
11. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
[TBL] [Abstract][Full Text] [Related]
12. Activated steady status and distinctive FcεRI-mediated responsiveness in basophils of atopic dermatitis.
Imamura S; Washio K; Mizuno M; Oda Y; Fukunaga A; Nishigori C
Allergol Int; 2021 Jul; 70(3):327-334. PubMed ID: 33674191
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
15. IgE and high-affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance.
Giménez-Arnau AM; Ribas-Llauradó C; Mohammad-Porras N; Deza G; Pujol RM; Gimeno R
Clin Transl Allergy; 2022 Feb; 12(2):e12117. PubMed ID: 35126995
[TBL] [Abstract][Full Text] [Related]
16. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
18. FcεRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy.
Berings M; Gevaert P; De Ruyck N; Derycke L; Holtappels G; Pilette C; Bachert C; Lambrecht BN; Dullaers M
Clin Exp Allergy; 2018 Aug; 48(8):970-980. PubMed ID: 29682789
[TBL] [Abstract][Full Text] [Related]
19. Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients.
Platzer MH; Grattan CE; Poulsen LK; Skov PS
Allergy; 2005 Sep; 60(9):1152-6. PubMed ID: 16076300
[TBL] [Abstract][Full Text] [Related]
20. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
